NDC 72903-853

ELAHERE

Mirvetuximab Soravtansine

ELAHERE is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Immunogen, Inc.. The primary component is Mirvetuximab Soravtansine.

Product ID72903-853_0a19fa56-07a8-46b8-ab69-f6c83d725d56
NDC72903-853
Product TypeHuman Prescription Drug
Proprietary NameELAHERE
Generic NameMirvetuximab Soravtansine
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2022-11-14
Marketing CategoryBLA /
Application NumberBLA761310
Labeler NameImmunoGen, Inc.
Substance NameMIRVETUXIMAB SORAVTANSINE
Active Ingredient Strength100 mg/20mL
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 72903-853-01

1 VIAL, SINGLE-USE in 1 CARTON (72903-853-01) > 20 mL in 1 VIAL, SINGLE-USE
Marketing Start Date2022-11-14
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [ELAHERE]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ELAHERE
ELAHERE
97676672 not registered Live/Pending
ImmunoGen, Inc.
2022-11-14
ELAHERE
ELAHERE
97676668 not registered Live/Pending
ImmunoGen, Inc.
2022-11-14
ELAHERE
ELAHERE
90488884 not registered Live/Pending
ImmunoGen, Inc.
2021-01-26
ELAHERE
ELAHERE
90009729 not registered Live/Pending
ImmunoGen, Inc.
2020-06-18
ELAHERE
ELAHERE
88268164 not registered Live/Pending
ImmunoGen, Inc.
2019-01-18

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.